Journal of Hebei Medical University

Previous Articles     Next Articles

Efficacy and safety of Aprazole combined with Somatostatin in the treatment of severe acute pancreatitis

  

  1. Department of Gastroenterology, Haikou Hospital Affiliated to Xiangya School of Medicine, Central South University, Hainan Province, Haikou 570208, China
  • Online:2019-11-25 Published:2019-11-21

Abstract: [Abstract] Objective〖HTSS〗To investigate the efficacy and safety of Aprazole combined with Somatostatin in treating severe acute pancreatitis and the regulation role of oxidative stress level.
〖HTH〗〖WTHZ〗Methods〖HTSS〗Ninety-eight severe acute pancreatitis patients were selected and randomly divided into treatment group and control group with 49 cases in each group according to the random number table. Both groups received routine therapy referring to “Guidelines for the diagnosis and treatment of acute pancreatitis in China”. Control group was given with Somatostatin. Based on treatment of control group,treatment group was treated with Iprazole enteric-coated tablet(2 tablets/time and qd). Both groups were treated for ten-days. Time of symptoms recovery for both groups were recorded. Rates of multiple organ dysfunction syndrome(MODS) and acute respiratory dysfunction syndrome(ARDS), death rate were recorded for two  groups within four weeks after treatment. Adverse reactions were recorded during treatment for two groups. Levels of superoxide dismutase(SOD), malondialdehyde(MDA),and glutathione peroxidase(GSH-Px) were detected for two groups.
〖HTH〗〖WTHZ〗Results〖HTSS〗Time of the recovery of abdominal pain, distention,gurgling sound, defecation and body temperature in treatment group were shorter than control one(P<0.05). The ARDS and MODS rates of treatment group were 12.24% and 10.2%, wich were evidently lower than control group within four weeks(P<0.05). There was no statistically significant difference in death rate for two groups(P>0.05). The incidence of headache, dizziness, nausea and vomiting, diarrhea, rash and chest tightness were not statistically significant between two groups(P>0.05). After treatment,serum levels of SOD and GSH-Px of treatment group were evidently higher,while MDA  was lower,than control group with significant differences(P<0.05).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗Based on routine therapy, aprazole combined with somatostatin in treating severe acute pancreatitis can promote improvement of symptoms, decrease rates of ARDS and MODS,has good security,and the regulation role of oxidative stress level may be related with the efficacy.

Key words: pancreatitis, acute necrotizing, somatostatin; aprazole